New test could transform diagnosis and treatment of STIs
A new rapid test for sexually transmitted infections could soon transform on-the-spot diagnosis and treatment.
Birmingham-based Linear Diagnostics has secured £1 million in funding to develop the technology, which could deliver results in less than 20 minutes.
The funding comes from the NIHR Invention for Innovation programme and will support a three-year project to finalise the test and prepare it for clinical trials.
Dr Jean-Louis Duprey, head of research and development at Linear Diagnostics, said: "We are developing a near patient device that will overcome this conundrum."
The company is working with the NIHR HealthTech Research Centre and the North East Innovation Lab to deliver the project.
Dr Jana Suklan, senior methodologist at the HRC, said: "The NIHR HRC in Diagnostic and Technology Evaluation is delighted to be collaborating with the North East Innovation Lab to support Linear Diagnostics with their exciting technology.
"Our research involves analysing unmet needs, examining current practice and identifying the most promising point in the patient pathway for implementing the technology."
The test uses Linear's Exponential Amplification (EXPAR) technology, which detects bacterial DNA within minutes.
The company has focused on STIs such as Neisseria gonorrhoeae and Chlamydia trachomatis, where rapid diagnosis is essential to prevent further transmission and begin treatment immediately.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
The CEO building the 'Ikea of factories' wants to democratize semiconductor production
In his 1986 book "Engines of Creation," engineer K. Eric Drexler — often called the godfather of nanotechnology — made a prediction. "The coming era of molecular machines will mean the end of many limits: the limit of scarcity, the limit of slow development, the limit of ignorance enforced by the lack of tools," he wrote. Reading those words a few years later, when he was 16, Matthew Putman started thinking. "Our bodies work as these little micro-machines where you have ribosomes and enzymes and things that are working and replicating and making things all the time, but our factories work the way that they've worked for the last hundred years," Putman told Business Insider he thought at the time. He wondered how a world would look "where you don't have large assembly lines, you don't have smokestacks, you instead just make things so perfectly," he said. Putman became fascinated by the possibilities of machines that are "atomically precise." It wasn't until the recent AI boom, however, that the idea really took off with fabrication plants. Putman, now 50, is the CEO of Brooklyn-based Nanotronics, which he cofounded with his father in 2010. The company started out building microscopes and tools to detect defects in semiconductors, among other materials. Now, it builds small, modular semiconductor manufacturing plants called Cubefabs. While the biggest fabs in the country are often millions of square feet in size, Cubefabs measure anywhere from 25,000 square feet for the smallest units up to about 60,000 square feet for a full-sized fab. They're adaptable, and the company says they can be assembled in under a year in most places on Earth. They're also smart — thanks to the power of AI — so they can self-monitor their production and improve in real time, the company said. And they're relatively cheap, costing a minimum of $30 to $40 million, compared to large fabs that can cost billions to build. With President Donald Trump back in the White House and pledging to reinvigorate US manufacturing, a new opening has emerged for Nanotronics — even as sweeping tariffs challenge companies that produce or depend on semiconductors. Putman says that in the long term, the tariffs will bolster domestic innovation. Tariffs "should be a wake-up call — a push to create something better than what either the US or China has done before," he told BI in a video interview from the Nanotronics headquarters in Brooklyn Navy Yard. "If we get this right, American innovation won't just protect our future — it could help redefine global progress in a way that benefits humanity." Putman says compact, modular factories are exactly that. "Your factory should be incredibly small," Putman said, gesturing to the room behind him. "Eventually, it could be the size of this room." The 'Ikea of factories' Semiconductor manufacturing has surged since the launch of ChatGPT. Global annual revenue for the industry is expected to reach more than $1 trillion by 2030, according to McKinsey & Company. In the US, despite legislation subsidizing domestic semiconductor production, fabs are more expensive to construct and maintain than those built in places like mainland China and Taiwan, McKinsey says. The US also suffers from a shortage of qualified labor, which can delay construction timelines, according to the firm. To attempt to solve some of these issues, Nanotronics teamed up with architecture firm Rogers Partners and engineering firm Arup to design compact factories. Each one runs with 37 people, but Putman says the ideal setup is four factories — about 180 workers total — which allows them to scale up without halting production. "It's like the Ikea of factories," Putman said. The company has raised $182 million to date from firms including Peter Thiel's Founders Fund. Cubefabs can be used to produce chips that span a range of uses across electronics applications, electric vehicles, and photodetectors for cube satellites, Putman said. "The more precise we make things, the more abundance we bring to the world," he said. "The business of making things grow bigger and bigger starts small — molecular small." Building on the foundational research of scientist Philippe Bove — now chief scientist at Nanotronics — the company also uses gallium oxide — a type of semiconductor that can handle more power than traditional materials like silicon — to produce advanced chips. The company plans to have its first installation set up in New York within the next 18 months. "These fabs do not require billions in capital expenditure or large populations of highly trained workers," Putman told BI in a follow-up email. "The vision is that any region — whether in the Global South or the United States — should be able to produce what it needs locally."
Yahoo
5 hours ago
- Yahoo
Nightclub worker diagnosed with brain tumour reveals key early sign
A Birmingham nightclub worker was diagnosed with a brain tumour after getting lost in a place he knew "like the back of his hand". Tom Weatherstone, from Sheldon, had visited Perranporth in Cornwall all his life but couldn't find his way back from the beach in summer 2022. After he was diagnosed, he said his confusion may have been the first sign something was wrong. READ MORE: Dad who built £180k back garden bungalow for ill father has days to tear it down He also started having headaches, sickness and blurry pixelated vision in his right eye but his family believed they were linked to his job and lifestyle. He was diagnosed less than a year later after he was sent for blood tests and a CT scan by a doctor who spotted his hand tremors during a routine and unrelated private appointment in March 2023. The now-23-year-old was previously told he had a vitamin deficiency following a telephone consultation with his GP and was prescribed vitamin B12, D and folic acid. He was told he needed surgery to treat it, which could result in him losing his sight, his memory, his mobility or even his speech. Tom said: 'Retrospectively, the first sign came earlier, during a family holiday in the summer of 2022. 'One day, I walked back from the beach and got lost in a place I had known my whole life like the back of my hand. "At the time, it seemed odd, but we didn't think much of it. Looking back, it was the beginning of something none of us could have imagined.' READ MORE: City station attacker who 'bit and clawed' police dies at bail hostel Tom's oldest sister, Josie, 27, said: 'When Tom started having headaches, throwing up, vision problems, and noticing a tremor in his hand, we put it down to his lifestyle and assumed his job in a nightclub, the noise and bright lights were the cause. 'After Tom was diagnosed with a mineral deficiency, none of us thought it was a symptom of a brain tumour.' Tom continued: 'I had more bloods taken, another CT scan, and a sight test done at Heartlands Hospital in March 2023. 'By early the next morning, they confirmed again there was something there. 'I was transferred that same day to the Queen Elizabeth Hospital in Birmingham. I remember the anxiety building. 'I was scared. I just wanted to know what was in my head that was causing so much alarm.' At the QE, Tom was diagnosed with an astrocytoma, a tumour which develops from star-shaped glial cells, and had urgent surgery to fit a shunt to relieve pressure on his brain and a biopsy. He said: 'Doctors said the risks of surgery were loss of sight, mobility, memory or even speech loss. 'I was on my own, no family, and the doctor just said: 'It's a tumour'. I didn't know what to say. 'I rang my family straight away, I was in shock, devastated. 'I'd gone to the doctor for a routine check and now I was in hospital with a brain tumour.' Tom had a second operation on May 22 2023 to 'debulk' the tumour, which resulted in the partial loss of peripheral vision in his right eye. READ MORE: Hero police officer saves woman from dog attack which nearly killed her Five days later, Tom returned home to recover, but at his follow-up appointment, he was given the devastating news that the tumour had progressed from grade 2 to grade 4. He said: 'When I heard it was grade 4, I put on a brave face, but inside I was crushed. 'I stayed positive, I had to, but it wasn't easy.' Tom underwent six weeks of radiotherapy, followed by a year of chemotherapy. In December 2024, an MRI scan revealed a second astrocytoma, inoperable due to its sensitive location, but stable. A third tumour is not responding to treatment. He now undergoes MRI scans every three months. Now Josie and Tom's younger sister Gemma, 19, are taking on the 88 Squats a Day in July challenge to raise money for Brain Tumour Research in support of Tom and others affected. They can be backed on their JustGiving page here. Josie said: 'If we'd known Tom's symptoms were those of a brain tumour, we'd have taken him straight to hospital. 'I'm taking on the 88 Squats a Day Challenge for Tom because no-one should have to go through what he has. 'Watching someone you love face a brain tumour is heartbreaking. 'If raising awareness and money helps even one family get an earlier diagnosis or better treatment, every squat is worth it.' Get the latest BirminghamLive news direct to your inbox Katrina Jones, head of community and digital fundraising at Brain Tumour Research, said: 'We're incredibly grateful to Josie for taking on the 88 Squats Challenge in support of Tom. 'Her determination and strength are truly inspiring. 'Brain tumours are the biggest cancer killer of children and adults under 40 in the UK, yet research into them remains severely underfunded. 'Supporters like Josie play a vital role in helping us fund the research needed to improve outcomes and ultimately find a cure." Brain Tumour Research funds sustainable research at dedicated centres in the UK. It also campaigns for the Government and larger cancer charities to invest more in research into brain tumours to speed up new treatments for patients and, ultimately, find a cure. The charity is the driving force behind the call for a national annual spend of £35 million to improve survival rates and patient outcomes in line with other cancers such as breast cancer and leukaemia.
Yahoo
6 hours ago
- Yahoo
Birmingham GP practice issues Mounjaro statement and the five boxes patients must tick
A Birmingham GP surgery has urged patients not to book appointments for weight loss drug Mounjaro after it was made available on the NHS. The medication was made available for weight loss prescription via GPs from this week. But Sutton Coldfield Group Practice, which includes a number of surgeries in the town, said it was not yet clear how it would be offered locally. READ MORE: Major update over Three Mobile compensation after network went down READ MORE: I live in 'UK's worst council house' in Birmingham - now the ceiling's falling in READ MORE: City station attacker who 'bit and clawed' police dies at bail hostel And it said it would initially only be available to those with a BMI of more than 40 and who had four weight-related health conditions. The full message, which the Practice issued on Facebook, read: "You may have heard that from June 23, 2025, GPs can prescribe Tirzepatide (Mounjaro) for weight loss. "However, the Birmingham and Solihull Integrated Care Board is still finalising how this will be provided. It is expected to be offered through local clinics, as there has been no planning from the ICB to provide it via individual GP practices. "Initially, the treatment will be available only to people with a BMI over 40 who also have four weight-related health conditions such as high blood pressure, high cholesterol, sleep apnoea, heart disease, or type 2 diabetes. "Please do not book appointments specifically to request this medication at this time, as this service is not yet operational. "We will notify you as soon as the service is available. When it starts, eligible patients will be invited to participate. Doctors will review patient records to identify those who qualify." Around 220,000 people with the 'greatest need' are expected to receive Mounjaro through the NHS over the next three years. It is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. And pharmacy experts also said there could be pressure on supplies. Prof Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. More widely, while weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they must not be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.'
